Brucellosis causing bone marrow aplasia in an 11-year-old patient with complete recovery after treatment
Nour Youssef,
Yolla Youssef,
Dolly Noun,
Miguel Abboud,
Ghassan Dbaibo
Affiliations
Nour Youssef
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, Lebanon; Center for Infectious Diseases Research, American University of Beirut Medical Center, Beirut, Lebanon
Yolla Youssef
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, Lebanon; Center for Infectious Diseases Research, American University of Beirut Medical Center, Beirut, Lebanon
Dolly Noun
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Miguel Abboud
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Ghassan Dbaibo
Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, Lebanon; Center for Infectious Diseases Research, American University of Beirut Medical Center, Beirut, Lebanon; Corresponding author at: Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Brucellosis is one of the most prevalent zoonotic infections in the Middle East. The disease may present with a range of symptoms from a simple febrile illness to severe invasive infections affecting different organ systems (meningitis, osteomyelitis). In this paper we present an eleven-year-old girl who was diagnosed with “idiopathic bone marrow aplasia” and planned for hematopoietic stem cell transplant (HSCT), when pre-transplant work-up showed high brucella titers. The patient was started on doxycycline, rifampin and gentamicin initially, with discontinuation of the latter 3 weeks into therapy. She recovered completely after 8 months of treatment.
